Aurobindo Pharma Ltd

BSE: 524804 NSE: AUROPHARMA
Aurobindo Pharma Ltd - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L24239TG1986PLC015190 Incorporated 26 December 1986 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: AUROPHARMA · BSE: 524804 Public Limited Company pharma Fortune India 500 · #87 Nifty 500
Data last updated
Market Cap
₹90,841 Cr
AUROPHARMA · NSE
Share Price
₹1,610.90
+2.03% today
Revenue
₹33,653 Cr
FY 2025-26 · +6.1% YoY
EBITDA
₹6,780 Cr
Margin 20.1%
Net Profit
₹3,563 Cr
FY 2025-26 · +3.2% YoY
P/E (TTM)
24.7x
P/B 2.5x
ROE
9.9%
ROCE 12.4%
Debt / Equity
0.23
Interest cover 7.7x

About Aurobindo Pharma Ltd

Data last updated:

Aurobindo Pharma Ltd is a public limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 26 December 1986 and has been in existence for over 40 years.

Aurobindo Pharma is ranked #87 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices. Its director PV Ramprasad Reddy is #67 among India's richest people (2026). Its director Nityananda Reddy and family are #389 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24239TG1986PLC015190. Its GSTIN is 36AABCA7366H1ZL (Telangana). The company holds 36 GST registrations, of which 23 are active. Its shares are listed on BSE: 524804 and NSE: AUROPHARMA.

The company has an authorised share capital of ₹666.4 Cr and a paid-up capital of ₹57.54 Cr. It was formerly known as Aurobindo Pharma Pvt Ltd. It is led by directors including Nityananda Reddy Kambam (Managing Director) and Madan Mohan Reddy Mettu (Whole-Time Director).

Its last annual general meeting (AGM) was held on 10 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No.2 Maithrivihar Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, India – 500038.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹33,653 Cr, a growth of 6.1% compared to the previous year. For the same year it recorded a net profit of ₹3,563 Cr (net margin 10.6%) and EBITDA of ₹6,780.4 Cr (EBITDA margin 20.1%). The net worth stands at ₹37,896 Cr (up 16% YoY). Total assets are valued at ₹47,134 Cr (up 14.2% YoY).

The company has about 15,925 employees on its provident fund (EPFO) records. Its group structure includes 17 subsidiaries and 2 joint ventures.

The company is associated with 3 brands: Auronext Pharma, Aurobindo Pharma and Tergene Biotech. As per MCA filings, the company has open charges of ₹2,000 Cr and satisfied charges of ₹4,387.54 Cr on record. Court records list 1,329 cases involving the company, including 1,104 filed by the company and 225 filed against it; 293 cases are pending. The company has 73 deals on record (61 market trades, 11 funding rounds, 1 secondary share transfer), with disclosed funding of ₹242.92 Cr; the latest was in October 2025. Its 7 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 5 smaller; the largest is Sun Pharmaceutical Industries Limited with revenue of ₹54,543 Cr. The company has 18 MSME Form 1 returns on record between 2019 and 2024, listing 5,935 overdue payments to 593 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aurobindo.com.

Company details

CIN L24239TG1986PLC015190
Registration Number 015190
Incorporation Date 26 December 1986
ROC Hyderabad
Listing Status Listed (BSE: 524804, NSE: AUROPHARMA)
Company Status Active
Date of Last AGM 10 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant

CIN history

Aurobindo Pharma has one previous CIN (Corporate Identification Number): L24239AP1986PLC015190. The current CIN is L24239TG1986PLC015190, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24239TG1986PLC015190Current
L24239AP1986PLC015190Previous
Key People
Nityananda Reddy Kambam Managing Director Madan Mohan Reddy Mettu Whole-Time Director Girish Paman Vanvari Director

Recognitions & Rankings of Aurobindo Pharma

Fortune India 500 2025 edition
Rank#87
Total income
₹32,943 Cr
Profit
₹3,486 Cr
Last year #80
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#92
Valuation
₹72,630 Cr
2023 #91 2022 #132 2021 #101
Stock market indices
Nifty 500 BSE 500

Contact details

Aurobindo Pharma Ltd's registered office is in Hyderabad, Telangana. Its website is aurobindo.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    aurobindo.com
  • Social Media
  • Registered Address
    Plot No.2 Maithrivihar Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, India – 500038
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Aurobindo Pharma Ltd, buy the company report.

Comprehensive company report
Aurobindo Pharma Ltd - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Aurobindo Pharma operates multiple associated brands including Auronext Pharma, Aurobindo Pharma, and Tergene Biotech. Each brand links to its own profile.

BrandDescriptionWebsite
Aurobindo Pharma
Generic biocatalytic solutions are provided for pharmaceutical applications.aurobindo.com
Tergene Biotech
Bio-conjugate technologies for bacterial vaccines and conjugates are developed.tergene.com
Auronext Pharma
Offers comprehensive outsourced API production services for the pharmaceutical industry.auronext.com

Business activity

The main business activity of Aurobindo Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Aurobindo Pharma Ltd, buy the company report.

Financials of Aurobindo Pharma Ltd

FY 2025-26 filings available

Aurobindo Pharma Ltd reported revenue of ₹33,653 Cr (up 6.1% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹33,653 Cr
+6.1% YoY
EBITDA
₹6,780 Cr
+3.5% YoY
Profit After Tax
₹3,563 Cr
+3.2% YoY
Net Worth
₹37,896 Cr
+16.0% YoY
Total Assets
₹47,134 Cr
+14.2% YoY
Total Debt
₹8,068 Cr
-2.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue33,65331,72429,00224,85523,45524,77523,099
Revenue growth+6.1%+9.4%+16.7%+6.0%-5.3%+7.3%-
EBITDA6,7806,5515,6343,7074,1124,8434,823
EBITDA margin+20.2%+20.7%+19.4%+14.9%+17.5%+19.6%+20.9%
Profit before tax5,1125,0664,3802,6123,3737,3443,743
Net profit3,5633,4533,2731,9202,7573,4102,865
Net profit margin+10.6%+10.9%+11.3%+7.7%+11.8%+13.8%+12.4%
EPS (₹)60.3460.0254.1632.9045.2091.0548.56
Balance sheet
Total assets47,13441,26136,77632,35227,63827,51922,813
Net worth37,89632,65629,84326,84024,57621,93016,825
Total debt8,0688,2616,6485,2862,8515,3395,826
Cash & bank9,8708,2356,2786,0844,1905,4742,842
Net working capital20,90018,94215,78214,16111,87113,90310,590
Cash flow
Cash from operations5,5263,9252,4352,3875,0163,3294,381
Cash from investing(2,630)(1,866)(4,242)(3,971)(3,211)597(1,563)
Cash from financing(1,269)1208001,814(2,969)(1,365)(1,947)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9,1508,8538,6468,2867,8688,3827,9797,796
Revenue growth (YoY)+16.3%+5.6%+8.4%+6.3%+4.0%---
Other income264117188122107135159136
EBITDA1,8391,7501,7081,6781,6031,7601,5781,566
EBITDA margin+20.2%+20.0%+19.9%+20.4%+20.6%+21.0%+20.0%+20.5%
Depreciation487479465429406444419382
Interest10298.2192.7795.2497.75115118113
Profit before tax1,5151,2911,3391,2761,2071,3351,2001,207
Tax483370429428383432354391
Net profit1,032921910848824903846817
EPS (₹)17.8615.8615.6714.6114.2015.5614.5614.00
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue11,17210,93310,6468,45711,28715,82413,371
Revenue growth+2.2%+2.7%+25.9%-25.1%-28.7%+18.4%-
EBITDA3,0752,5582,2241,4901,3994,1202,698
EBITDA margin+27.5%+23.4%+20.9%+17.6%+12.4%+26.0%+20.2%
Profit before tax3,1642,3582,4571,6161,6374,1932,370
Net profit2,4271,7371,9511,2171,5363,1131,879
Net profit margin+21.7%+15.9%+18.3%+14.4%+13.6%+19.7%+14.1%
EPS (₹)41.5830.0833.3520.9424.8353.1332.03
Balance sheet
Total assets27,07625,23422,63022,32419,01719,95216,837
Net worth22,71820,53419,72318,03417,11715,92513,052
Total debt4,2854,6472,8614,2031,8954,0283,741
Cash & bank16229894.3437350.7838686.16
Net working capital5,1965,5124,8347,4477,4889,4458,646
Cash flow
Cash from operations2,9331,6461,7151,8163,7272,9942,201
Cash from investing(1,996)(2,050)(152)(3,230)(1,615)(2,650)(948)
Cash from financing(1,072)616(1,837)1,719(2,448)(27.94)(1,255)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,8002,7872,7472,7902,8482,7322,9172,825
Revenue growth (YoY)-1.7%+2.0%-5.8%-1.2%+15.8%---
Other income24221413016083.7711454.26123
Total expenses1,9172,0051,9752,0652,0522,1352,2032,104
EBITDA882781772725796597713721
EBITDA margin+31.7%+28.4%+28.3%+26.3%+28.2%+21.9%+24.7%+26.1%
Depreciation68.9971.9371.9271.4970.0293.8868.2868.16
Interest47.0747.2748.4357.4560.0061.0966.1951.63
Profit before tax1,008876782755750556633724
Tax271184200174191147161186

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9,1508,8538,6468,2867,8688,3827,9797,796
Revenue growth (YoY)+16.3%+5.6%+8.4%+6.3%+4.0%---
Other income264117188122107135159136
EBITDA1,8391,7501,7081,6781,6031,7601,5781,566
EBITDA margin+20.2%+20.0%+19.9%+20.4%+20.6%+21.0%+20.0%+20.5%
Depreciation487479465429406444419382
Interest10298.2192.7795.2497.75115118113
Profit before tax1,5151,2911,3391,2761,2071,3351,2001,207
Tax483370429428383432354391
Net profit1,032921910848824903846817
EPS (₹)17.8615.8615.6714.6114.2015.5614.5614.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue33,65331,72429,00224,85523,45524,77523,099
Revenue growth+6.1%+9.4%+16.7%+6.0%-5.3%+7.3%-
Other income4946225572914363,630192
Total expenses26,87325,17323,36821,14819,34419,93218,276
Employee cost5,1904,4763,9233,5223,4513,5353,219
EBITDA6,7806,5515,6343,7074,1124,8434,823
EBITDA margin+20.2%+20.7%+19.4%+14.9%+17.5%+19.6%+20.9%
Depreciation1,7781,6491,5221,2451,1271,055967
Interest38445729014048.6474.49305
Profit before tax5,1125,0664,3802,6123,3737,3443,743
Tax1,6091,5831,2116857262,010899
Net profit3,5633,4533,2731,9202,7573,4102,865
Net profit margin+10.6%+10.9%+11.3%+7.7%+11.8%+13.8%+12.4%
EPS (₹)60.3460.0254.1632.9045.2091.0548.56
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital62.6360.3558.5958.5958.5958.5958.59
Reserves & surplus37,83332,59529,78426,78124,51721,87116,766
Shareholders' funds (net worth)37,89632,65629,84326,84024,57621,93016,825
Minority interest(8.16)(6.39)8.0012.00(1.93)(0.88)0.14
Secured loans4,1193,9553,9682,5575441,0541,315
Unsecured loans3,9494,3062,6792,7292,3084,2864,511
Total debt8,0688,2616,6485,2862,8515,3395,826
Total liabilities47,13441,26136,77632,35227,63827,51922,813
Assets
Gross block29,25124,46323,44818,59315,52513,61312,441
Net block17,40714,79414,49311,02410,5329,3749,396
Capital work in progress5,2144,9003,8695,3903,7473,0621,986
Investments1,051252372543997591555
Inventories12,05310,5449,8108,5167,5599,0417,700
Sundry debtors7,0945,7464,8174,4664,0123,5034,315
Cash & bank balances9,8708,2356,2786,0844,1905,4742,842
Loans & advances2,9442,6372,8182,2471,9881,6601,555
Total current assets31,96227,16223,72421,31417,74919,67816,412
Total current liabilities11,0628,2207,9417,1535,8785,7755,823
Net working capital20,90018,94215,78214,16111,87113,90310,590
Total assets47,13441,26136,77632,35227,63827,51922,813
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash5,5643,3854,3924,1635,3272,7691,876
Net cash from operating activities5,5263,9252,4352,3875,0163,3294,381
Net cash from investing activities(2,630)(1,866)(4,242)(3,971)(3,211)597(1,563)
Net cash from financing activities(1,269)1208001,814(2,969)(1,365)(1,947)
Net change in cash1,6282,178(1,007)230(1,164)2,561871
Closing cash9,8708,2356,2786,0844,1905,4742,842
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.1%+9.4%+16.7%+6.0%-5.3%+7.3%-
EBITDA growth+3.5%+16.3%+52.0%-9.8%-15.1%+0.4%-
PBT growth+0.9%+15.7%+67.7%-22.5%-54.1%+96.2%+21.1%
Net income growth+3.2%+5.5%+70.5%-30.4%-19.2%+19.0%-
Revenue CAGR (3Y)+10.6%+10.6%+5.4%+2.5%+6.2%+14.6%+15.7%
EBITDA CAGR (3Y)+22.3%+16.8%+5.2%-8.4%+2.1%+8.7%+12.0%
Profitability & leverage
Net income margin+10.4%+11.0%+10.9%+7.8%+11.3%+21.5%+12.3%
Return on capital employed+12.4%+14.2%+13.5%+9.2%+12.4%+18.3%+18.5%
Return on net worth+9.9%+11.2%+11.2%+7.5%+11.4%+17.6%+18.5%
Debt / equity0.230.240.210.160.180.290.42
Long-term debt / equity0.040.070.060.030.020.020.01
Interest cover7.689.337.045.711.631.977.91
Efficiency & per share
Fixed asset turnover1.251.321.381.461.611.902.01
Inventory turnover2.983.123.173.092.832.963.09
Debtors turnover5.246.016.255.866.246.345.98
EPS (₹)60.3460.0254.1632.9045.2091.0548.56
Dividend per share (₹)4.000.004.507.509.004.003.00
Book value per share (₹)652.39562.21509.35458.10419.46374.29287.16
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,8002,7872,7472,7902,8482,7322,9172,825
Revenue growth (YoY)-1.7%+2.0%-5.8%-1.2%+15.8%---
Other income24221413016083.7711454.26123
Total expenses1,9172,0051,9752,0652,0522,1352,2032,104
EBITDA882781772725796597713721
EBITDA margin+31.7%+28.4%+28.3%+26.3%+28.2%+21.9%+24.7%+26.1%
Depreciation68.9971.9371.9271.4970.0293.8868.2868.16
Interest47.0747.2748.4357.4560.0061.0966.1951.63
Profit before tax1,008876782755750556633724
Tax271184200174191147161186
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue11,17210,93310,6468,45711,28715,82413,371
Revenue growth+2.2%+2.7%+25.9%-25.1%-28.7%+18.4%-
Other income588328670444671590389
Total expenses8,0978,3768,4226,9679,88811,70410,673
Employee cost1,1611,0639818911,6001,7351,577
EBITDA3,0752,5582,2241,4901,3994,1202,698
EBITDA margin+27.5%+23.4%+20.9%+17.6%+12.4%+26.0%+20.2%
Depreciation285297255243415488473
Interest21323018374.5816.9428.68243
Profit before tax3,1642,3582,4571,6161,6374,1932,370
Tax7496125033891831,080493
Net profit2,4271,7371,9511,2171,5363,1131,879
Net profit margin+21.7%+15.9%+18.3%+14.4%+13.6%+19.7%+14.1%
EPS (₹)41.5830.0833.3520.9424.8353.1332.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital58.0858.0858.5958.5958.5958.5958.59
Reserves & surplus22,66020,47619,66417,97517,05915,86612,994
Shareholders' funds (net worth)22,71820,53419,72318,03417,11715,92513,052
Secured loans1,9061,8421,4321,9232898421,314
Unsecured loans2,3802,8041,4292,2801,6063,1862,427
Total debt4,2854,6472,8614,2031,8954,0283,741
Total liabilities27,07625,23422,63022,32419,01719,95216,837
Assets
Gross block4,6334,2314,0436,2155,7256,8206,181
Net block2,5442,3372,4193,6883,5864,4724,418
Capital work in progress22987.53133239225735815
Investments17,56215,21013,3938,1056,5845,0102,527
Inventories2,3612,3592,3684,1253,3564,8414,360
Sundry debtors4,2104,1953,7774,5603,9735,9285,785
Cash & bank balances16229894.3437350.7838686.16
Loans & advances5638371,0019062,4551,0931,058
Total current assets7,2967,6897,2399,9659,83512,24911,288
Total current liabilities2,1002,1782,4062,5182,3472,8032,642
Net working capital5,1965,5124,8347,4477,4889,4458,646
Total assets27,07625,23422,63022,32419,01719,95216,837
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash29583.3235751.1338467.3568.70
Net cash from operating activities2,9331,6461,7151,8163,7272,9942,201
Net cash from investing activities(1,996)(2,050)(152)(3,230)(1,615)(2,650)(948)
Net cash from financing activities(1,072)616(1,837)1,719(2,448)(27.94)(1,255)
Net change in cash(135)212(274)306(335)316(1.35)
Closing cash16229894.3437350.7838686.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+2.2%+2.7%+25.9%-25.1%-28.7%+18.4%-
EBITDA growth+20.2%+15.0%+49.3%+6.5%-66.1%+52.7%-
PBT growth+34.1%-4.0%+52.1%-1.3%-61.0%+76.9%+20.6%
Net income growth+39.7%-11.0%+60.3%-20.8%-50.7%+65.7%-
Revenue CAGR (3Y)+9.7%-1.1%-12.4%-14.2%-2.7%+15.5%+11.7%
EBITDA CAGR (3Y)+27.3%+22.3%-18.6%-18.0%-16.6%+15.6%+4.4%
Profitability & leverage
Net income margin+21.6%+16.0%+18.4%+14.5%+12.9%+19.7%+14.0%
Return on capital employed+12.9%+10.8%+11.7%+8.2%+8.5%+23.0%+16.0%
Return on net worth+11.2%+8.7%+10.4%+7.0%+8.8%+21.5%+15.4%
Debt / equity0.210.190.190.170.180.270.34
Long-term debt / equity0.010.010.000.000.000.000.00
Interest cover7.6410.189.275.981.720.7910.94
Efficiency & per share
Fixed asset turnover2.522.642.081.421.802.432.30
Inventory turnover4.734.633.282.262.753.443.21
Debtors turnover2.662.742.551.982.282.702.43
EPS (₹)41.5830.0833.3520.9424.8353.1332.03
Dividend per share (₹)4.000.004.507.509.004.003.00
Book value per share (₹)391.14353.55336.62307.80292.15271.80222.78

To see the full year-wise statements and ratios of Aurobindo Pharma Ltd, buy the company report.

Board of directors of Aurobindo Pharma Ltd

Aurobindo Pharma has 9 current directors and 22 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Girish Paman Vanvari
Also directs: Transaction Square LLP, Transaction Square Consultancy LLP, Himadri Speciality Chemical Limited and 5 more
Director05 Nov 20205 Years 11 MonthsCurrent
Venkata Ramprasad Reddy Penaka
Also directs: Penaka Pharma (India) Private Limited, RPR Sons Advisors Private Limited
Director30 Dec 199233 Years 9 MonthsCurrent
Madan Mohan Reddy Mettu
Also directs: MSS Packaging Industries LLP, Engenra Biologics Private Limited, Curateq Biologics Private Limited and 5 more
Whole-Time Director01 Jan 201313 Years 9 MonthsCurrent
Sarath Chandra Reddy Penaka
Also directs: Aurobindo Pharma Foundation, Sarath Penaka Enterprises LLP, Naqsh Global Ventures LLP and 4 more
Director27 Sep 200719 Years 0 MonthsCurrent
Nityananda Reddy Kambam
Also directs: Aurobindo Antibiotics Private Limited, Apl Healthcare Limited, Apitoria Pharma Private Limited and 5 more
Managing Director30 Dec 199233 Years 9 MonthsCurrent
Santanu Mukherjee
Also directs: Apitoria Pharma Private Limited, Suven Life Sciences Limited, Sumedha Fiscal Services Ltd and 4 more
Director09 Feb 20233 Years 8 MonthsCurrent
Showing 6 of 9 current directors. View all directors

Peer comparison

Aurobindo Pharma Ltd is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Sun Pharmaceutical Industries Limited₹54,543 Cr (FY 2025)9.0%Vadodara, Gujarat, India
Dr.Reddy's Laboratories Ltd₹33,741 Cr (FY 2025)17.0%Hyderabad, Telangana, India
Aurobindo Pharma Ltdthis company₹33,653 Cr (FY 2026)₹3,563 Cr10.6%6.1%15,925Hyderabad, Telangana, India
Cipla Limited₹28,409 Cr (FY 2025)7.0%Mumbai, Maharashtra, India
Zydus Lifesciences Limited₹23,511 Cr (FY 2025)19.0%Ahmedabad, Gujarat, India
Lupin Limited₹22,904 Cr (FY 2025)14.0%Mumbai, Maharashtra, India
Intas Pharmaceuticals Limited₹21,241 Cr (FY 2025)7.0%Ahmedabad, Gujarat, India
Hetero Labs Limited₹16,537 Cr (FY 2025)13.0%Hyderabad, Telangana, India

To see the full peer comparison of Aurobindo Pharma Ltd, buy the company report.

Auditor

Aurobindo Pharma Ltd is audited by Deloitte Haskins & Sells for the financial year 2024.

Auditor firmFinancial yearFirm registration number
Deloitte Haskins & SellsFY 2024008072S

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 51.90%, foreign institutional investors hold 16.40%, domestic institutional investors hold 25.10% and retail and other public shareholders hold 6.60%.

Promoters: 51.90%DII (Domestic Institutional): 25.10%FII (Foreign Institutional): 16.40%Retail & Others: 6.60%
Sep 2026
QUARTER
51.90% Promoters
25.10% DII (Domestic Institutional)
16.40% FII (Foreign Institutional)
6.60% Retail & Others
Promoter holding - history
Now 51.90% · Sep 2026High 51.90% · Sep 2026Low 51.80% · Dec 2025
50%50.8%51.5%52.3%53%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 51.80%Mar 2026: 51.80%Jun 2026: 51.80%Sep 2026: 51.90%51.80%51.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters51.90%51.80%51.80%51.80%
Public48.10%48.20%48.20%48.20%

Charges & borrowings

Open charges
₹2,000 Cr
Satisfied charges
₹4,387.54 Cr
Breakdown by lending institutions
State Bank of India₹2,000.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
05 Jun 199780013576State Bank of India₹2,000 CrOpen
08 Jan 201310402714Dbs Bank Ltd₹164 CrSatisfied
25 May 201210359357Ifci Limited₹156 CrSatisfied
25 May 201210359358Ifci Limited₹130 CrSatisfied
28 Feb 201110269583Axis Bank Limited₹37.98 CrSatisfied

To see the full charge records of Aurobindo Pharma Ltd, buy the company report.

Total charge records: 44 View all charges

Deals & funding

Aurobindo Pharma Ltd has 73 deals on record (61 market trades, 11 funding rounds, 1 secondary share transfer), with disclosed funding of ₹242.92 Cr; the latest was in October 2025.

Total deals
73
Market trades
61
Funding rounds
11
Secondary share transfer
1
Disclosed funding
₹242.92 Cr

Deals on record (5 of 73)

WhenDealAmountParties
Oct 2025Market trade₹11.76 CrBuyer: Goldman Sachs Bank Europese - Odi
Seller: Goldman Sachs Public Market Fund
Feb 2009Market trade₹13.69 CrBuyer: Top Class Capital Markets Private Limited
Feb 2009Market trade₹5.53 CrBuyer: Top Class Capital Markets Private Limited
Feb 2009Market trade₹13.52 CrBuyer: Top Class Capital Markets Private Limited
Feb 2009Market trade₹6.8 CrBuyer: Top Class Capital Markets Private Limited

To see the full deal history of Aurobindo Pharma Ltd, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Aurobindo Pharma Ltd was last rated by Indiarating on 20 Oct 2022.

Rating agencyRated onRating
Indiarating20 Oct 2022

To see the full credit ratings and regulatory alerts of Aurobindo Pharma Ltd, buy the company report.

MSME payment delays

Aurobindo Pharma Ltd has 18 MSME Form 1 returns on record between 2019 and 2024, listing 5,935 overdue payments to 593 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 593)

SupplierAmount dueDue sinceReported on
Sri Balaji Gases & Chemicals
Nitika Pharmaceutical Specialities Private Limited
Pranit Packaging Private Limited
Sri Maruti Packagings
Sri Sri Sairam Print Pack

To see the full MSME payment records of Aurobindo Pharma Ltd, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Aurobindo Pharma has 17 subsidiary companies, 2 joint ventures, and 2 associated companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

17
Subsidiary companies
2
Joint ventures
2
Associated companies
Key subsidiaries
Company NameCINShares held
Aurobindo Antibiotics Private LimitedU24110AP2020PTC115965
Curateq Biologics Private LimitedU24110TG2020PTC140190
Auroactive Pharma Private LimitedU24230TG2020PTC138313
Theranym Biologics Private LimitedU24230TG2022PTC166946
Auro Peptides LimitedU24232TG2012PLC078350
Apl Healthcare LimitedU24239TG2006PLC052053

To see the full group structure of Aurobindo Pharma Ltd, buy the company report.

Employees & EPFO

Aurobindo Pharma Ltd has a workforce of 15,925 employees on its EPFO records as of Aug 07, 2024, across 11 active EPFO establishments.

Employee count
15,925
Active EPFO establishments
11
Employee growth
-3.17%

GST

Aurobindo Pharma has 36 GST registrations: 23 active and 13 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
36
Active
23
Cancelled / inactive
13
GSTINStateStatusRegistered on
36AABCA7366H1ZLTelanganaActive01 Jul 2017
36AABCA7366H2ZKTelanganaActive01 Jul 2017
36AABCA7366H3ZJTelanganaActive02 Dec 2021
36AABCA7366H4ZITelanganaActive08 Mar 2025

To see the full GST registrations and return filing status of Aurobindo Pharma Ltd, buy the company report.

Recent activity

Aurobindo Pharma Ltd has 50 board changes on record since 1992: 31 appointments and 19 cessations. The latest: Punita Kumar Sinha was appointed as Director on 09 Feb 2026.

Appointed
Punita Kumar Sinha was appointed as Director.
AGM
Aurobindo Pharma Ltd last Annual general meeting of members was held on 10 Sep 2025 as per latest MCA records.
Filing
Aurobindo Pharma Ltd has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Ceased
Savita Mahajan ceased to be Director.
Appointed
Mangalam Ramasubramanian Kumar was appointed as Director.
Ceased
Ragunathan Kannan ceased to be Director.
Ceased
Avnit Bimal Singh ceased to be Director.
Appointed
Deepali Pant Joshi was appointed as Director.
Appointed
Satakarni Makkapati was appointed as Director.
Ceased
Sivakumaran Meenakshisunderam ceased to be Whole-Time Director.
Charges
A charge with State Bank Of India of Rs. 2,000.00 Cr registered on 05 Jun 1997 with Charge ID 80013576 was modified on 22 Feb 2023.
Appointed
Santanu Mukherjee was appointed as Director.

158 earlier events are in the company report.

News

Aurobindo Pharma: Co Acquires A1 Biochem Labs LLC For $15.247 Million, Completing The Purchase On October 2, 2026; A1 Labs Specializes In Contract Research Services For Pharmaceuticals.
02 Oct 2026 · Exchange Update

From our blog

Frequently asked questions

Aurobindo Pharma is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 26 December 1986 (40+ years old) and is registered under CIN L24239TG1986PLC015190. Listed on BSE: 524804 and NSE: AUROPHARMA.

Aurobindo Pharma reported revenue of ₹33,653 Cr for FY 2025-26 (up 6.1% YoY) based on consolidated financials.

Aurobindo Pharma has 9 current directors:

The latest financial statements of Aurobindo Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 10 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Aurobindo Pharma is 36AABCA7366H1ZL, registered in Telangana. The company has 36 GST registrations in all, of which 23 are active and 13 are cancelled or inactive. Other active GSTINs include 36AABCA7366H2ZK (Telangana), 36AABCA7366H3ZJ (Telangana), 36AABCA7366H4ZI (Telangana).

The CIN (Corporate Identification Number) of Aurobindo Pharma is L24239TG1986PLC015190. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Aurobindo Pharma is listed on both BSE (code: 524804) and NSE (symbol: AUROPHARMA).

Aurobindo Pharma has 1,329 court cases on record: 1,104 filed by the company and 225 filed against it. 293 are pending. Most are in the district courts.

Aurobindo Pharma was incorporated on 26 December 1986, making it 40+ years old. It is registered with the Registrar of Companies, Hyderabad.

Aurobindo Pharma has 73 deals on record (61 market trades, 11 funding rounds, 1 secondary share transfer), with disclosed funding of ₹242.92 Cr; the latest was in October 2025.

The peers of Aurobindo Pharma by revenue are Sun Pharmaceutical Industries Limited, Dr.Reddy's Laboratories Ltd, Cipla Limited, Zydus Lifesciences Limited, Lupin Limited and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Punita Kumar Sinha was appointed as Director on 09 Feb 2026. Savita Mahajan ceased to be Director on 16 Dec 2024. Mangalam Ramasubramanian Kumar was appointed as Director on 01 Apr 2024. Aurobindo Pharma has 50 board changes on record in total.